GATC Health Presents “Bridging the AI Gap” at Deep Pharma Intelligence Conference on April 5, 2022

IRVINE, CA, April 1, 2022—GATC Health, a biotech company revolutionizing drug discovery and disease prediction using artificial intelligence and advanced multiomics, today announced that the company will present at Deep Pharma Intelligence’s AI in Drug Discovery, Biomarker Development and Advanced R&D conference on the 5th of April, 2022. Preetaman Wadhwa, the company’s Chief Marketing Officer, will present “Bridging the AI Gap,” which addresses the company’s unique ability to deliver 10 or fewer potential drug candidate molecules per project using proprietary multiomics-based artificial intelligence.

“We feel that GATC Health could be the first company to bridge the AI gap,” stated Ms. Wadhwa. “From what we’ve seen in the market, our closest competitor can deliver between 130 to 500 molecules per project. That means their pharma partners needs to invest significant time and money to further test every one of those molecules to determine which, if any, will make it into clinical trials. Our platform, which mimics human biology and simulates therapeutic reponse, is able to deliver the exact molecule, or small group of molecules, per disease. Plus, we believe we can do this at least 50% faster than our nearest competitor, which translates to massive reductions in time, cost and risk to drugmakers.”

Deep Pharma Intelligence (DPI) is a leading strategic and investment intelligence agency focused on the emerging markets in the Pharmaceutical, BioTech, and Healthcare Tech industries.  DPI is producing regular analytical reports on major areas of high-potential in the pharmaceutical and healthcare industries, maintaining ratings of companies and governments based on their innovation potential and business activity in the BioTech space, and providing strategic consulting and investment intelligence services to top-tier clients.

In a recent report, DPI stated, “GATC Health[‘s] Platform significantly differentiates from its competitors. It has a human-like environment for disease modelling, a sophisticated combination of different AI approaches, computation chemistry, physics and biology and a unique proprietary database. These enable the company to close the AI gap by providing 1-3 de-risked compounds in minimal terms in 3-6 months.”

Deep Pharma Intelligence:AI in Drug Discovery, Biomarker Development and Advanced R&D Conference

Sign up to attend the virtual conference: https://lnkd.in/eHwUAqj7

Date: 5th of April, 2022

Time: 5 p.m GMT

# # #

About GATC HealthGATC Health Corp is a pioneering technology company using whole genome analysis and multiomics-based artificial intelligence to revolutionize disease detection and drug discovery. The company’s patented AI platform reduces risk, time and costs for life science companies by digitally reproducing the human body to find non-obvious answers to biology’s most complex questions. GATC Health is accelerating healthcare’s transition to predictive, individualized medicine.Disclaimer

The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities.  This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information.  The Company reserves the right to modify or amend the information contained herein.